Our top pick for
Avalon GloboCare Corp is a medical care facilities business based in the US. Avalon GloboCare shares (AVCO) are listed on the NASDAQ and all prices are listed in US Dollars. Avalon GloboCare employs 6 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$0.90 - $2.19|
|50-day moving average||$1.10|
|200-day moving average||$1.19|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.19|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$1.3 million|
|Gross profit TTM||$338,530|
|Return on assets TTM||-74.95%|
|Return on equity TTM||-295.49%|
|Market capitalisation||$86.1 million|
TTM: trailing 12 months
There are currently 1.6 million Avalon GloboCare shares held short by investors – that's known as Avalon GloboCare's "short interest". This figure is 14.4% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting Avalon GloboCare shares can be evaluated.
Avalon GloboCare's "short interest ratio" (SIR) is the quantity of Avalon GloboCare shares currently shorted divided by the average quantity of Avalon GloboCare shares traded daily (recently around 470183.43023256). Avalon GloboCare's SIR currently stands at 3.44. In other words for every 100,000 Avalon GloboCare shares traded daily on the market, roughly 3440 shares are currently held short.
However Avalon GloboCare's short interest can also be evaluated against the total number of Avalon GloboCare shares, or, against the total number of tradable Avalon GloboCare shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avalon GloboCare's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Avalon GloboCare shares in existence, roughly 20 shares are currently held short) or 0.0576% of the tradable shares (for every 100,000 tradable Avalon GloboCare shares, roughly 58 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Avalon GloboCare.
Find out more about how you can short Avalon GloboCare stock.
We're not expecting Avalon GloboCare to pay a dividend over the next 12 months.
Avalon GloboCare's shares were split on a 1:4 basis on 17 October 2016. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Avalon GloboCare shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Avalon GloboCare shares which in turn could have impacted Avalon GloboCare's share price.
Over the last 12 months, Avalon GloboCare's shares have ranged in value from as little as $0.9 up to $2.1935. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avalon GloboCare's is 0.433. This would suggest that Avalon GloboCare's shares are less volatile than average (for this exchange).
Avalon GloboCare Corp. , together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology. In addition, the company develops proprietary diagnostic and therapeutic products leveraging exosome technology; and provides development services for hospitals. The company has a strategic partnership with Weill Cornell Medical College to co-develop bio-production and standardization procedures for chimeric antigen receptor (CAR)-T Therapy; GensKey Medical Technology Co. Ltd.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.